Dr. Reddy’s Laboratories Limited filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2026, with the United States Securities and Exchange Commission on May 29, 2026. The filing contains the company's annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), as issued by the International Accounting Standards Board (IASB). This submission provides transparency into the pharmaceutical company's financial performance and compliance with US regulatory requirements for the period.

The Annual Report on Form 20-F is accessible on Dr. Reddy’s website. American Depositary Receipts (ADRs) holders may obtain a hard copy of the report at no cost by sending a written request to the company’s registered office or via email to shares@drreddys.com .

Filing Details

Dr. Reddy’s Laboratories Limited is listed on the BSE (500124), NSE (DRREDDY), NYSE (RDY), and NSEIFSC (DRREDDY). The company operates as a global pharmaceutical entity headquartered in Hyderabad, India.

Dr. Reddy's Laboratories Ltd. recorded a notable block trade on the National Stock Exchange, with approximately 1,45,522 shares changing hands in a single transaction. The trade was executed at a price of ₹1336.00 per share, aggregating to a total deal value of ₹19.44 crores.

Block Trade Details

The following table summarises the key parameters of the block trade:

About Block Trades

Block trades represent large-volume transactions typically executed by institutional investors, mutual funds, or other significant market participants. These trades are generally conducted outside the regular order book to minimise market impact and are reported separately on the exchange platform. The identity of the buyer and seller in such transactions is not disclosed as part of the standard block deal reporting.